Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 17%
Hold 67%
Sell 6%
Strong Sell 0%

Bulls say

Amgen is poised for strong top-line growth in 2026 and beyond, driven not only by key commercial products like Repatha and Tezspire, but also by the continued strength of its rare disease segment, particularly its drug Uplizna. The company's positive 1Q 2026 performance, with sales and EPS beating estimates, is a testament to its strong product portfolio and pipeline, making it an attractive investment with an overweight rating and a PT of $427.

Bears say

Amgen is a biotechnology-based human therapeutics company that has a solid portfolio of flagship drugs, including Epogen, Aranesp, Neupogen, and Enbrel, among others. However, the company faces headwinds in the near future due to competition from generic drugs and slower-than-expected sales for certain products. These factors, along with increased concerns about regulatory and pricing risks, lead to a negative outlook for the company's financial performance.

Amgen (AMGN) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 18 analysts, Amgen (AMGN) has a Hold consensus rating as of Jul 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $356.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $356.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.